| 영문 | opioid | 한글 | 아편유사제 |
|---|---|---|---|
| 설명 | 1. 아편제제와 같은 작용을 가진 합성마약으로서 아편유도체가 아닌 것. 종류로는 heroin, meperidine, dihydromorphine(Dilaudid), methadone 등이 있다. 2. 세포막의 아편제제 수용체와 상호작용함으로써 아편제제와 같은 효과를 나타내는 천연산 펩티드. |
||
| 영문 | agonist | 한글 | 작용제, 작용근 |
|---|---|---|---|
| 설명 | 1. 수용체와 결합하여 최대의 약리작용을 발현하는 화학물질을 말한다. 수용체에 특이하게 친화성을 가지고 있다. 생체 안에서 생산되는 내인성인 것과 생체 밖에서 투여되는 외인성인 것이 있다. 부분 작용제는 수용체와 결합해도 100%의 약리작용을 발현하지는 않으며 용량을 증가시켜도 효과는 커지지 않는다. 2. 해부학에서는 주가 되어 움직이는 근육의 무리 |
||
| PAA | partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas... |
|---|---|
| PR | by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr... |
| POP | diphosphate group; pain on palpation; paroxypropione; persistent occipitoposterior [fetal position];... |
| IHSS(= HCMP) | Idiopathic Hypertrophic Subaortic Stenosis = Obstructive Idiopathic Hypertrophic Car... |
| ORA | opiate receptor agonist |
| R,S | receptor agonist |
|---|---|
| 8-OH-DPAT | 5-HT agonist 8-hydroxy-2-(di-n-propylamino) tetralin |
| 8-OH-DPAT | 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin |
| (35)S | Agonist-stimulated |
| GNRH-a | GnRH agonist |
| opioid partial agonist | <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response. (16 Dec 1997) |
|---|
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
|---|---|
| opioid agonist | <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression. (16 Dec 1997) |
| agonist | 1. <anatomy> A prime mover. 2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response. (18 Nov 1997) |
| calcium channel agonist | <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (12 Dec 1998) |
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| muscarinic agonist | Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| LH and RH agonist | <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer. (14 Oct 1997) |
| analgesics, opioid | Narcotic or opioid substances, synthetic or semisynthetic agents producing profound analgesia, drowsiness, and changes in mood. Mood changes may be pleasurable, therefore creating a potential for the abuse of these agents; the prototype of these is morphine to which all other analgesics are compared. (12 Dec 1998) |
| receptors, opioid | Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behaviour of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. (12 Dec 1998) |
| receptors, opioid, delta | A class of opioid receptors recognised by its pharmacological profile. Delta opioid receptors bind endorphins and enkephalins with approximately equal affinity and have less affinity for dynorphins. (12 Dec 1998) |
| receptors, opioid, kappa | A class of opioid receptors recognised by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins. (12 Dec 1998) |
| receptors, opioid, mu | A class of opioid receptors recognised by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. (12 Dec 1998) |
| opioid | Originally, a term denoting synthetic narcotics resembling opiates but increasingly used to refer to both opiates and synthetic narcotics. (05 Mar 2000) |
| opioid antagonists | Agents such as naloxone and naltrexone which have high affinity for opiate receptors but do not activate these receptors. These drugs block the effects of exogenously administered opioids such as morphine, heroin, meperidine, and methadone, or of endogenously released endorphins and enkephalins. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|